Susan Greenspan
Endocrinology · Pittsburgh, PANPI 1174596076
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $123 of the $162 with a category attached, or 75.6%. Every reported general payment came from a single manufacturer, Amgen.
Across 2 payments — averaging $81.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$162
Across 21 payments — averaging $172,613 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$3.6M
- Radius Health, Inc.$3K
What the payments were for
- Travel & lodging$4024%
- Food & beverage$12376%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 2 | $162 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$123
How this compares
$162 in reported general payments places this provider in the 65th percentile of 22 endocrinology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TymlosAbaloparatide | 37 | $106,458 |
| Teriparatide | 31 | $78,880 |
| Alendronate Sodium | 32 | $296 |
Paid to pharmacies, not to this prescriber.
Other endocrinology in Pittsburgh
- Diana PinkhasovaPittsburgh$2K
- Maja Stefanovic-RacicPittsburgh$491
- Steven HodakPittsburgh$190
- Sam JosephFeasterville Trevose$3K
- Mohammad ArastuBethlehem$2K
- Edward RubyDarby$2K
- Javier Ocampo MascaroPhiladelphia$671
- Julia KharlipPhiladelphia$0
- Daniel RubinPhiladelphia$0
- Hamdee AttallahPhiladelphia$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.